

Corresponding author(s):	Ai-Long Huang
Last updated by author(s):	Apr 17, 2020

## **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

_				
C-	ŀэ	ŤΙ	ıct	icc

Sta	atistics				
For	all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Confirmed				
	The exact sam	ple size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement			
	A statement o	n whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
$\boxtimes$	A description	of all covariates tested			
$\times$	A description	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons			
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
$\boxtimes$	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.				
$\times$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
$\boxtimes$	$\square$ Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated				
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.			
Software and code					
Poli	cy information abou	ut <u>availability of computer code</u>			
Da	ata collection	No commercial, open source software, custom code was used in data collection.			
Da	ata analysis	Statistical analyses were performed using R software, version 3.6.0.			
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research <u>guidelines for submitting code &amp; software</u> for further information.					

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data  $% \left( 1\right) =\left( 1\right) \left( 1\right) \left($
- A description of any restrictions on data availability

Raw data in this study are provided in the Supplementary Dataset. Additional supporting data are available from the corresponding authors on request. All request for raw and analyzed data and materials will be reviewed by the corresponding authors to verify whether the request is subject to any intellectual property or confidentiality obligations.

Field-spe	cific reporting				
Please select the or	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
X Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences				
For a reference copy of t	he document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
Life scier	nces study design				
All studies must dis	close on these points even when the disclosure is negative.				
Sample size	We did not perform statistical analyses to predetermine sample sizes. By 12th Feb, 2020, a total of 426 confirmed COVID-19 patients were admitted to three designated hospitals. 124 patients were reluctant to offer their blood samples while 17 Samples from 17 patients are not qualified for serology testing (hemolysis, lipemia). Therefore, 285 COVID-19 patients were included in this study.				
Data exclusions	All patients and serum were included.				
Replication	Precision and reproducibility experiments were conducted in triplicate or duplicate. The magnetic chemiluminescence enzyme immunoassay (MCLIA) for virus-specific antibody detection was proved with admirable precision and reproducibility. The antibody titer was tested one time for each serum sample in our study.				
Randomization	Our study is an observation study, so no randomization is needed here.				
Blinding	Serum extraction and antibody detection were performed independently by researchers blind to samples information, data analysis were performed by two trained researchers.				
Reporting for specific materials, systems and methods					
	on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, ed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Materials & exp	perimental systems Methods				
n/a Involved in th	e study n/a Involved in the study				
Antibodies	ChIP-seq				
Eukaryotic					
Palaeontol					
Animals and other organisms					
Clinical dat	a en				
Antibodies					
Antibodies used	Alkaline Phosphatase–conjugated Affinipure Goat Anti-Human IgG, Catalog number: SA00002-8, Proteintech.				
Validation	The antibody was only used for the application as indicated and organisms verified by the manufactures.				
Human rese	arch participants				
Policy information about studies involving human research participants					
Population characteristics For the cross-sectional cohort, the median age was 47 years, ranged from 7 months to 84 years, and 158 of 285 were male. For					

the follow up cohort, the median age was 49 ranged from 11 to 84 years, and 36 of 63 were male.

1) Confirmed COVID-19 patients (two positive RT-PCR results from nasal and pharyngeal swab specimens). 2) Patients were Recruitment

recruited from 3 designated hospitals in Chongqing city, China. 3) Patients agreed to be enrolled.

Ethics oversight Chongqing Medical University

Note that full information on the approval of the study protocol must also be provided in the manuscript.